Spinal injury
An eight-year-old boy has rallied his family to join him on a 330-mile charity challenge to safeguard a life-changing spinal cord injury rehabilitation programme which has supported him.
Jasper Thornton-Jones was paralysed aged two after a spinal stroke. Key to his rehabilitation therapy since then has been the Neurokinex Charitable Trust, based near Gatwick. Jasper was the first paediatric client at Neurokinex when he started there in September 2016 on its Step Up Scheme. The initiative has proved life-changing for many patients, and offers a set of six free rehab sessions for adults and children with a new spinal cord injury. The scheme costs the Neurokinex Charitable Trust £420 per person to fulfil and relies on funding for its survival.
What began as a small Facebook group has now become the UK’s leading voice on Cauda Equina Syndrome.
The Cauda Equina Champions Charity is an active campaigner to achieve greater recognition of the condition, among medical professionals and the public alike, with a lack of knowledge leading to many people being undiagnosed and suffering in silence. The syndrome is a rare and severe type of spinal stenosis where the nerves in the lower back suddenly become severely compressed, and failure to diagnose and receive appropriate treatment can lead to greater risk of long-term consequences including incontinence or paralysis.
Brain and spinal cord scars in people with multiple sclerosis (MS) may reveal why they develop progressive disabilities, research suggests.
Suicidal risk and understanding how best to respond was the subject of a recent webinar for professionals working with brain and spinal injured clients. Assessments including how to assess the different levels of risk, including looking out for red flags, primary drivers and secondary drivers, were all addressed to empower people to deal with what [...]
If injury or illness means living life your way isn’t easy, live-in care can provide support. Agincare is experienced in supporting people with acquired brain injuries, acquired spinal cord injuries and more diverse neurological needs.
As a family owned and run business and one of England’s largest care groups, we’re proud to have been delivering skilled and professional care with a smile for 35 years. If you’re looking for round-the-clock support without compromising on your choice, lifestyle, or independence, live-in care is designed for you. To discover the difference that live-in care can make, we’d like you to meet Callum. Callum’s story Callum is no less an adrenaline junkie today than he was as a teenager. Unfortunately, at age 16, while having fun with friends, Callum fell 30 feet. He sustained trauma to his head, memory loss and an acquired spinal cord injury. Callum spent the next two years in hospital. With his mobility declining and behavior becoming challenging, Callum’s social worker decided to research live-in care.
Erin Pollitt suffered a serious spinal injury in her second year of professional dance training.
While practicing a difficult move during rehearsals at the Northern School for Contemporary Dance in Leeds, she fell to the floor and suddenly felt a sharp pain at the base of her spine. She was booked in to see the school’s physio the next day, feeling the full impact of the fall after being unable to walk properly or move as she normally could.
A newly-developed device which can be implanted into the spinal column to treat severe pain could also be a potential treatment for paralysis.
The ultra-thin inflatable invention, which is about the width of a human hair, can be rolled up into a tiny cylinder, inserted into a needle, and implanted into the epidural space of the spinal column - the same area where injections are administered to control pain during childbirth. Once correctly positioned, the device - developed by engineers and clinicians at the University of Cambridge - is inflated with water or air so it unrolls like a tiny air mattress, covering a large section of the spinal cord. When connected to a pulse generator, the ultra-thin electrodes start sending small electrical currents to the spinal cord, which disrupt pain signals.
Understanding suicidal risk and supporting professionals to deal with such a hugely difficult topic is to be tackled in an event being held next week.
Life-changing brain, spinal cord and complex injuries can be significant factors in increasing this risk, as a result of the huge spectrum of difficult emotions a person faces in dealing with their new reality. And for the professionals dealing with clients going through such trauma, suicidal thoughts and acts can cause great distress to them and it can be difficult to know how to react and what action to take. Through the ‘Understanding Suicidal Risk - A Guide for Professionals’ event, held by Sphere Memory and Rehabilitation Team, advice and guidance will be offered to empower those working in complex injury to deal with such situations.
Health tech business ONWARD has secured its third Breakthrough Device Designation status as it continues towards its goal of commercialising its technology which could allow paralysed patients to walk again.
The venture secured Breakthrough Device Designation for its ARC-IM platform for blood pressure and trunk control in people with spinal cord injury. It is the third such status awarded to ONWARD from the US Food and Drug Administration (FDA), following previous awards for ARC-EX for upper extremity function and ARC-IM for mobility. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The system is operated via a tablet programmer and smartwatch.
People living with spinal cord injury can experience lasting pain relief through the injection of micro-fragmented adipose tissue (MFAT) for rotator cuff disease, new research has revealed.
A team of specialists in regenerative rehabilitation have shown through a pilot study that MFAT can deliver benefits to wheelchair users who experience shoulder problems. In the study, nearly 80 per cent of participants saw a meaningful decrease in pain symptoms through an ultrasound-guided injection of MFAT, and all but one reported some improvement in pain and function. Scores also declined steadily over the first three months for all metrics, and over the entire year for the BPI-17 pain metric, suggesting that this intervention has long-lasting effects.
